Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia.

The mutational status of tumor immunoglobulin V(H) genes is providing a powerful prognostic marker for chronic lymphocytic leukemia (CLL), with patients having tumors expressing unmutated V(H) genes being in a less favorable subset. However, the biologic differences correlating with V(H) gene status that could determine the clinical course of the disease are unknown. Here we show that differing responses to IgM ligation are closely associated with V(H) gene status. Specifically, 80% of cases with unmutated V(H) genes showed increased global tyrosine phosphorylation following IgM ligation, whereas only 20% of samples with mutated V(H) genes responded (P =.0002). There was also an association between response to IgM ligation and expression of CD38 (P =.015). The Syk kinase, critical for transducing B-cell receptor (BCR)- derived signals, was constitutively present in all CLL samples, and there was a perfect association between global phosphorylation and induction of phosphorylation/activation of Syk. Nonresponsiveness to anti-IgM could be circumvented by ligation of IgD (10 of 15 samples tested) or the BCR-associated molecule CD79alpha (12 of 15 samples tested). These results suggest that multiple mechanisms underlie nonresponsiveness to anti-IgM in CLL and that retained responsiveness to anti-IgM contributes to the poor prognosis associated with the unmutated subset of CLL. The prognostic power of the in vitro response to IgM ligation remains to be determined in a large series, but the simple technology involved may present an alternative or additional test for predicting clinical course.

[1]  D. Oscier,et al.  CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. , 2002, Blood.

[2]  G. Capelli,et al.  Clinical significance of CD38 expression in chronic lymphocytic leukemia. , 2001, Blood.

[3]  K. Do,et al.  CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. , 2001, Blood.

[4]  M. Gold,et al.  New views of BCR structure and organization. , 2001, Current opinion in immunology.

[5]  M Chilosi,et al.  Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. , 2001, Blood.

[6]  R. Rosenquist,et al.  CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. , 2001, Blood.

[7]  Randall L. Kincaid,et al.  Phosphorylation of Syk Activation Loop Tyrosines Is Essential for Syk Function , 2000, The Journal of Biological Chemistry.

[8]  T J Hamblin,et al.  Immunoglobulin V genes and CD38 expression in CLL. , 2000, Blood.

[9]  M. Dono,et al.  Apoptosis or plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD. , 2000, Blood.

[10]  Stevenson,et al.  Recognition of Auto‐ and Exoantigens by V4‐34 Gene Encoded Antibodies , 2000, Scandinavian journal of immunology.

[11]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[12]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[13]  P. Circosta,et al.  An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia. , 1999, Blood.

[14]  Tetsuya Nakamura,et al.  Antigen-Stimulated Dissociation of BCR mIg from Ig-α/Ig-β: Implications for Receptor Desensitization , 1999 .

[15]  M. Scott,et al.  Cold agglutinin activity is common among human monoclonal IgM Rh system antibodies using the V4‐34 heavy chain variable gene segment , 1997, Transfusion.

[16]  V. Lang,et al.  Normal Syk protein level but abnormal tyrosine phosphorylation in B-CLL cells , 1997, Leukemia.

[17]  A. A. Thompson,et al.  Aberrations of the B-cell receptor B29 (CD79b) gene in chronic lymphocytic leukemia. , 1997, Blood.

[18]  S. Zupo,et al.  CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. , 1996, Blood.

[19]  M. Cragg,et al.  The development of anti-CD79 monoclonal antibodies for treatment of B-cell neoplastic disease. , 1995, Therapeutic immunology.

[20]  C. Chapman,et al.  Pattern of usage of the VH4-21 gene by B lymphocytes in a patient with EBV infection indicates ongoing mutation and class switching. , 1995, Molecular immunology.

[21]  M. Reth,et al.  The B cell antigen receptor of class IgD induces a stronger and more prolonged protein tyrosine phosphorylation than that of class IgM , 1995, The Journal of experimental medicine.

[22]  J. Monroe,et al.  Differential responsiveness of immature- and mature-stage murine B cells to anti-IgM reflects both FcR-dependent and -independent mechanisms. , 1992, Cellular immunology.

[23]  P. Youinou,et al.  CD5-induced apoptosis of B cells in some patients with chronic lymphocytic leukemia , 2002, Leukemia.

[24]  P. Musto,et al.  CD79b expression in B-cell chronic lymphocytic leukemia. , 2000, Haematologica.

[25]  Terry J. Hamblin,et al.  Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia , 1999 .

[26]  T J Hamblin,et al.  B-cell chronic lymphocytic leukemia: a bird of a different feather. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  C. Goodnow,et al.  Positive versus negative signaling by lymphocyte antigen receptors. , 1998, Annual review of immunology.

[28]  R. V. van Lier,et al.  Antigen receptor nonresponsiveness in chronic lymphocytic leukemia B cells. , 1995, Blood.